Study of ALXN2050 in Adult Participants With Generalized Myasthenia Gravis

Phase 2 Terminated 70 enrolled Alexion Pharmaceuticals, Inc.

RandomizedParallel-groupTriple-blindTreatment

Summary

This study will evaluate the efficacy and safety of ALXN2050 (120 milligrams \[mg\], 180 mg) in participants with generalized myasthenia gravis (gMG). Safety will be monitored throughout the study.

Timeline

Start: 2022-04-27
Primary completion: 2023-11-30
Completion: 2024-04-03

Publications

Sacca F, Gialdini G, Howard JF Jr, Vu TH, Meisel A, Peric S, Lunemann JD, Sgarzi M, Shaibani A, Bril V, Yeh JH, Reyes-Garrido V, Liao S, Metais C, van der Valk RJP; ALXN2050-MG-201 Investigators. Efficacy and Safety of Vemircopan in Generalized Myasthenia Gravis: A Randomized Clinical Trial. JAMA Neurol. 2026 Jun 1;83(6):544-553. doi: 10.1001/jamaneurol.2026.0902.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Vemircopan	Small molecule	120 mg	Oral
Subject	Vemircopan	Small molecule	180 mg	Oral

Study of ALXN2050 in Adult Participants With Generalized Myasthenia Gravis

Summary

Timeline

Publications

Drugs

Indications